B-intervention	0	11	Trastuzumab
I-intervention	12	16	plus
I-intervention	17	28	anastrozole
O	29	35	versus
B-control	36	47	anastrozole
I-control	48	53	alone
O	54	57	for
O	58	61	the
O	62	71	treatment
O	72	74	of
O	75	89	postmenopausal
O	90	95	women
O	96	100	with
O	101	106	human
O	107	116	epidermal
O	117	123	growth
O	124	130	factor
O	131	139	receptor
O	140	141	2
O	141	142	-
O	142	150	positive
O	150	151	,
O	152	159	hormone
O	160	168	receptor
O	168	169	-
O	169	177	positive
O	178	188	metastatic
O	189	195	breast
O	196	202	cancer
O	202	203	:
O	204	211	results
O	212	216	from
O	217	220	the
O	221	231	randomized
O	232	237	phase
O	238	241	III
O	242	248	TAnDEM
O	249	254	study
O	254	255	.

O	256	262	TAnDEM
O	263	265	is
O	266	269	the
O	270	275	first
O	276	286	randomized
O	287	292	phase
O	293	296	III
O	297	302	study
O	303	305	to
O	306	313	combine
O	314	315	a
O	316	324	hormonal
O	325	330	agent
O	331	334	and
O	335	346	trastuzumab
O	347	354	without
O	355	367	chemotherapy
O	368	370	as
O	371	380	treatment
O	381	384	for
O	385	390	human
O	391	400	epidermal
O	401	407	growth
O	408	414	factor
O	415	423	receptor
O	424	425	2
O	426	427	(
O	427	431	HER2
O	431	432	)
O	432	433	/
O	433	440	hormone
O	441	449	receptor
O	449	450	-
O	450	460	copositive
O	461	471	metastatic
O	472	478	breast
O	479	485	cancer
O	486	487	(
O	487	490	MBC
O	490	491	)
O	491	492	.

B-eligibility	493	507	Postmenopausal
I-eligibility	508	513	women
I-eligibility	514	518	with
I-eligibility	519	523	HER2
I-eligibility	523	524	/
I-eligibility	524	531	hormone
I-eligibility	532	540	receptor
I-eligibility	540	541	-
I-eligibility	541	551	copositive
I-eligibility	552	555	MBC
O	556	560	were
O	561	569	randomly
O	570	578	assigned
O	579	581	to
O	582	593	anastrozole
O	594	595	(
O	595	596	1
O	597	599	mg
O	599	600	/
O	600	601	d
O	602	608	orally
O	608	609	)
O	610	614	with
O	615	617	or
O	618	625	without
O	626	637	trastuzumab
O	638	639	(
O	639	640	4
O	641	643	mg
O	643	644	/
O	644	646	kg
O	647	658	intravenous
O	659	667	infusion
O	668	670	on
O	671	674	day
O	675	676	1
O	676	677	,
O	678	682	then
O	683	684	2
O	685	687	mg
O	687	688	/
O	688	690	kg
O	691	696	every
O	697	701	week
O	701	702	)
O	703	708	until
O	709	720	progression
O	720	721	.

O	722	725	The
O	726	733	primary
O	734	737	end
O	738	743	point
O	744	747	was
B-outcome-Measure	748	759	progression
I-outcome-Measure	759	760	-
I-outcome-Measure	760	764	free
I-outcome-Measure	765	773	survival
I-outcome-Measure	774	775	(
I-outcome-Measure	775	778	PFS
I-outcome-Measure	778	779	)
O	780	782	in
O	783	786	the
O	787	793	intent
O	793	794	-
O	794	796	to
O	796	797	-
O	797	802	treat
O	803	813	population
O	813	814	.

O	815	822	Results
O	823	830	Overall
O	830	831	,
B-intervention-participants	832	835	103
O	836	844	patients
O	845	853	received
O	854	865	trastuzumab
O	866	870	plus
O	871	882	anastrozole
O	882	883	;
B-control-participants	884	887	104
O	888	896	received
O	897	908	anastrozole
O	909	914	alone
O	914	915	.

O	916	924	Patients
O	925	927	in
O	928	931	the
O	932	943	trastuzumab
O	944	948	plus
O	949	960	anastrozole
O	961	964	arm
O	965	976	experienced
O	977	988	significant
O	989	1001	improvements
O	1002	1004	in
B-outcome	1005	1008	PFS
O	1009	1017	compared
O	1018	1022	with
O	1023	1031	patients
O	1032	1041	receiving
O	1042	1053	anastrozole
O	1054	1059	alone
O	1060	1061	(
O	1061	1067	hazard
O	1068	1073	ratio
O	1074	1075	=
O	1076	1077	0
O	1077	1078	.
O	1078	1080	63
O	1080	1081	;
O	1082	1084	95
O	1084	1085	%
O	1086	1088	CI
O	1088	1089	,
O	1090	1091	0
O	1091	1092	.
O	1092	1094	47
O	1095	1097	to
O	1098	1099	0
O	1099	1100	.
O	1100	1102	84
O	1102	1103	;
B-outcome	1104	1110	median
I-outcome	1111	1114	PFS
O	1114	1115	,
B-iv-cont-median	1116	1117	4
I-iv-cont-median	1117	1118	.
I-iv-cont-median	1118	1119	8
O	1120	1121	v
B-cv-cont-median	1122	1123	2
I-cv-cont-median	1123	1124	.
I-cv-cont-median	1124	1125	4
I-cv-cont-median	1126	1132	months
O	1132	1133	;
O	1134	1137	log
O	1137	1138	-
O	1138	1142	rank
O	1143	1144	P
O	1145	1146	=
O	1147	1148	.
O	1148	1152	0016
O	1152	1153	)
O	1153	1154	.

O	1155	1157	In
B-outcome	1158	1166	patients
I-outcome	1167	1171	with
I-outcome	1172	1181	centrally
I-outcome	1182	1191	confirmed
I-outcome	1192	1199	hormone
I-outcome	1200	1208	receptor
I-outcome	1209	1219	positivity
O	1220	1221	(
O	1221	1222	n
O	1223	1224	=
O	1225	1228	150
O	1228	1229	)
O	1229	1230	,
B-outcome	1231	1237	median
I-outcome	1238	1241	PFS
O	1242	1245	was
B-iv-cont-median	1246	1247	5
I-iv-cont-median	1247	1248	.
I-iv-cont-median	1248	1249	6
O	1250	1253	and
B-cv-cont-median	1254	1255	3
I-cv-cont-median	1255	1256	.
I-cv-cont-median	1256	1257	8
I-cv-cont-median	1258	1264	months
O	1265	1267	in
O	1268	1271	the
O	1272	1283	trastuzumab
O	1284	1288	plus
O	1289	1300	anastrozole
O	1301	1304	and
O	1305	1316	anastrozole
O	1317	1322	alone
O	1323	1327	arms
O	1327	1328	,
O	1329	1341	respectively
O	1342	1343	(
O	1343	1346	log
O	1346	1347	-
O	1347	1351	rank
O	1352	1353	P
O	1354	1355	=
O	1356	1357	.
O	1357	1360	006
O	1360	1361	)
O	1361	1362	.

B-outcome	1363	1370	Overall
I-outcome	1371	1379	survival
O	1380	1382	in
O	1383	1386	the
O	1387	1394	overall
O	1395	1398	and
O	1399	1408	centrally
O	1409	1418	confirmed
O	1419	1426	hormone
O	1427	1435	receptor
O	1435	1436	-
O	1436	1444	positive
O	1445	1456	populations
O	1457	1463	showed
O	1464	1466	no
O	1467	1480	statistically
O	1481	1492	significant
O	1493	1502	treatment
O	1503	1513	difference
O	1513	1514	;
O	1515	1522	however
O	1522	1523	,
O	1524	1526	70
O	1526	1527	%
O	1528	1530	of
O	1531	1539	patients
O	1540	1542	in
O	1543	1546	the
O	1547	1558	anastrozole
O	1559	1564	alone
O	1565	1568	arm
O	1569	1576	crossed
O	1577	1581	over
O	1582	1584	to
O	1585	1592	receive
O	1593	1604	trastuzumab
O	1605	1610	after
O	1611	1622	progression
O	1623	1625	on
O	1626	1637	anastrozole
O	1638	1643	alone
O	1643	1644	.

B-outcome	1645	1654	Incidence
I-outcome	1655	1657	of
I-outcome	1658	1663	grade
I-outcome	1664	1665	3
I-outcome	1666	1669	and
I-outcome	1670	1671	4
I-outcome	1672	1679	adverse
I-outcome	1680	1686	events
O	1687	1690	was
B-iv-bin-percent	1691	1693	23
I-iv-bin-percent	1693	1694	%
O	1695	1698	and
B-iv-bin-percent	1699	1700	5
I-iv-bin-percent	1700	1701	%
O	1701	1702	,
O	1703	1715	respectively
O	1715	1716	,
O	1717	1719	in
O	1720	1723	the
O	1724	1735	trastuzumab
O	1736	1740	plus
O	1741	1752	anastrozole
O	1753	1756	arm
O	1756	1757	,
O	1758	1761	and
B-cv-bin-percent	1762	1764	15
I-cv-bin-percent	1764	1765	%
O	1766	1769	and
B-cv-bin-percent	1770	1771	1
I-cv-bin-percent	1771	1772	%
O	1772	1773	,
O	1774	1786	respectively
O	1786	1787	,
O	1788	1790	in
O	1791	1794	the
O	1795	1806	anastrozole
O	1807	1812	alone
O	1813	1816	arm
O	1816	1817	;
B-iv-bin-abs	1818	1821	one
O	1822	1829	patient
O	1830	1832	in
O	1833	1836	the
O	1837	1848	combination
O	1849	1852	arm
O	1853	1864	experienced
O	1865	1868	New
O	1869	1873	York
O	1874	1879	Heart
O	1880	1891	Association
O	1892	1897	class
O	1898	1900	II
B-outcome	1901	1911	congestive
I-outcome	1912	1917	heart
I-outcome	1918	1925	failure
O	1925	1926	.

O	1927	1938	Trastuzumab
O	1939	1943	plus
O	1944	1955	anastrozole
O	1956	1964	improves
O	1965	1973	outcomes
O	1974	1977	for
O	1978	1986	patients
O	1987	1991	with
O	1992	1996	HER2
O	1996	1997	/
O	1997	2004	hormone
O	2005	2013	receptor
O	2013	2014	-
O	2014	2024	copositive
O	2025	2028	MBC
O	2029	2037	compared
O	2038	2042	with
O	2043	2054	anastrozole
O	2055	2060	alone
O	2060	2061	,
O	2062	2070	although
O	2071	2078	adverse
O	2079	2085	events
O	2086	2089	and
O	2090	2097	serious
O	2098	2105	adverse
O	2106	2112	events
O	2113	2117	were
O	2118	2122	more
O	2123	2131	frequent
O	2132	2136	with
O	2137	2140	the
O	2141	2152	combination
O	2152	2153	.
